A team of researchers and program managers has received support from the National Institutes of Health (NIH) to determine the best practices that will help decrease the heavy burden diseases place on sub-Saharan Africa.
Leaders with the U.S. Food and Drug Administration (FDA) Advisory Committee recently recommended Jardiance, which decreases cardiovascular death rates among adults who have type 2 diabetes and cardiovascular disease, for approval with a 12-11 vote.
According to the American Heart Association (AHA) Rapid Access Journal Report, patients who have high cholesterol levels because of genetics are five times more likely to experience long-term risks of developing coronary heart disease and experiencing stroke.
Researchers recently published a study in the American Heart Association (AHA) Rapid Access Journal Report, stating that patients who have advanced heart failure may be helped by a video explaining their end-of-life care choices.
A recent release from the American College of Cardiology and the American Heart Association (AHA) provides adult patients with atrial flutter, or atrial fibrillation, with updated quality measures and clinical performance standards.
Boehringer Ingelheim recently announced that its phase-two study results show that the company’s new treatment, IL-23 inhibitor risankizumab, induces remission in patients who have moderate-to-severe Crohn’s disease.
A recent study from researchers at the National Institutes of Health (NIH) shows that endocannabinoids, which are the natural chemical messengers inside the body that are similar in effect to marijuana, are important in developing habits.
Pfizer Inc. recently announced that it has granted over $1 million to finance the top breast cancer advocacy organizations that are dedicated to scientific research and quality-of-life studies concerning metastatic breast cancer (MBC).